Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 4/20 | 0.47 |
| ▸ | RORC | P51449 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.43 |
| ▸ | APAF1 | O14727 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4063943 | 0.90 | NCF1 (0.45) | NCF1RORCCYP2C9SMN1; SMN2KMT2A | |
| SCHEMBL4060534 | 0.89 | KDM4E (0.46) | NCF1SMN1; SMN2KMT2AKDM4EMEN1 | |
| SCHEMBL4060598 | 0.84 | SMN1; SMN2 (0.42) | NCF1RORCSMN1; SMN2KMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL4063788 | 0.83 | SMN1; SMN2 (0.42) | NCF1RORCSMN1; SMN2KMT2AKDM4E | |
| SCHEMBL4060642 | 0.82 | RORC (0.45) | NCF1RORCCYP2C9SMN1; SMN2KMT2A | |
| SCHEMBL4062265 | 0.77 | NPC1 (0.45) | RORCCYP2C9SMN1; SMN2DHODHKMT2A | |
| SCHEMBL4060213 | 0.75 | HTR3A (0.54) | RORCCYP2C9KDM4ENPSR1MAPT | |
| SCHEMBL4065134 | 0.73 | HCAR2 (0.48) | RORCCYP2C9KDM4EPDE4AKCNH2 | |
| SCHEMBL4067501 | 0.72 | RORC (0.56) | RORCCYP2C9KDM4EPDE4AKCNH2 | |
| SCHEMBL4243255 | 0.72 | NR4A2 (0.61) | NCF1KMT2AKDM4EMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641791-B1 | 3-(GUANIDINOCARBONYL)HETEROCYCLE DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS, THEIR USE AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-07-29 | — | — | EP | disclosed |
| US-7230007-B2 | Derivatives of 3-(Guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-12 | — | — | US | disclosed |
| EP-1641791-A1 | 3-(GUANIDINOCARBONYL)HETEROCYCLE DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS, THEIR USE AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM | Sanofi-Aventis Deutschland GmbH (DE) | 2006-04-05 | — | — | EP | disclosed |
| US-20050014758-A1 | Derivatives of 3-(guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
| WO-2004111048-A1 | 3-(GUANIDINOCARBONYL)HETEROCYCLE DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS, THEIR USE AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014758-A1 | Derivatives of 3-(guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom | TNNI3, TNNT2, TNNC1 | NCF1 258/4885RORC 1476/4885CYP2C9 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.